
Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
Considerations for Treating Locally Advanced NSCLC
A 60-year-old Asian Woman With Unresectable, Locally Advanced NSCLC


